Pre-Clinical Evaluation of Hemoglobin Based Oxygen Carriers: Animal Models and Biomarkers

• Published in: Hemoglobin-Based Oxygen Carriers As Red Cell Substitutes and Oxygen Therapeutics pp. 457 - 474
• Main Authors: Buehler, Paul, D’Agnillo, Felice
• Format: Reference Book Chapter
• Language: English
• Published: Germany Springer Berlin / Heidelberg 2013; Springer Berlin Heidelberg
• Subjects: Antioxidant Depletion; Biochemistry; Biological markers; Clinical trials; Good Laboratory Practice; Hemoglobins; Materials science; Medical research; Preclinical Safety; Sickle Cell Disease; Sickle Cell Disease Patient
• ISBN: 9783642407161; 3642407161
• DOI: 10.1007/978-3-642-40717-8_26

The pre-clinical evaluation of hemoglobin (Hb) based oxygen carriers (HBOCs) consists of both proof of concept studies and studies to support safe use in clinical subjects. Certain HBOCs have demonstrated problematic safety profiles in human subjects, particularly in later phases of clinical trials when complicated and/or pre-existing disease states occur together. The mechanisms leading to adverse events in humans are likely related to nitric oxide (NO) interactions with Hb, but may also be associated oxidative toxicity in tissue. While the effects of NO on hypertension and vasculopathy are well established, limited data exist to support the role between Hb and oxidative tissue injury. The primary focus areas of this chapter are to (1) outline existing approaches to proof of concept studies for HBOCs and good laboratory practice (GLP) based studies to establish safe use in humans (2) suggest novel supportive approaches to pre-clinical evaluation using pre-existing disease state animal models and HBOC administration (3) propose novel markers of early tissue injury that may be beneficial in the study of HBOC safety and allow for additional understanding of human subject risk.